LAVAL, Quebec, Nov. 21, 2017 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)
("Valeant") today announced that Paul S.
Herendeen, executive vice president, Finance, and chief
financial officer, and Arthur J.
Shannon, senior vice president and head of Investor
Relations and Communications, are scheduled to participate at the
Evercore ISI Biopharma Catalyst/Deep Dive Conference in
Boston on Nov. 29, 2017 at 11:00
a.m. EST.
A live webcast and audio archive of the event will be available
on the Investor Relations page of the Valeant web site at:
http://ir.valeant.com/events-and-presentations/2017.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@valeant.com
|
lainie.keller@valeant.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-evercore-isi-biopharma-catalystdeep-dive-conference-300558427.html
SOURCE Valeant Pharmaceuticals International, Inc.